|
CA-125 in Screening Patients at High Risk for Ovarian Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on CA-125 in Screening Patients at High Risk for Ovarian Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. CA-125 in Screening Patients at High Risk for Ovarian Cancer Clinical research trials and CA-125 in Screening Patients at High Risk for Ovarian Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like CA-125 in Screening Patients at High Risk for Ovarian Cancer. CA-125 in Screening Patients at High Risk for Ovarian Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a CA-125 in Screening Patients at High Risk for Ovarian Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their CA-125 in Screening Patients at High Risk for Ovarian Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > CA-125 in Screening Patients at High Risk for Ovarian Cancer  CA-125 in Screening Patients at High Risk for Ovarian Cancer
CA-125 in Screening Patients at High Risk for Ovarian Cancer
For Condition: ovarian epithelial cancer
Status: Recruiting
Sponsor(s): UAB Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Measuring levels of CA 125 in blood samples of women who have a high risk of developing ovarian cancer may help doctors detect cancer early and plan more effective treatment. PURPOSE: Phase II trial to study the effectiveness of monitoring CA-125 levels in screening for cancer in women who are at high risk of developing ovarian cancer.
Details: OBJECTIVES: Primary - Determine the feasibility of prospective screening for ovarian cancer in high-risk patients. - Determine normal ranges and distributions of CA 125 within and between these patients (with subclassification by menopausal status, estrogen replacement therapy usage, and prophylactic oophorectomy). Secondary - Determine estimates of the specificity and positive predictive value of a risk of cancer algorithm suitable for designing a definitive trial of screening for ovarian cancer in these patients. OUTLINE: This is a multicenter, pilot study. Patients undergo blood collection and CA 125 levels are measured at baseline and then every 3 months for 1-2 years. Patients may be referred for an ovarian ultrasound if indicated by the CA 125 results. Patients are followed at 6 months and then annually thereafter. PROJECTED ACCRUAL: A total of 2,400 patients will be accrued for this study within 1 year.
Eligibility:
Study Type: Observational, Screening
Minimum Age/Maximum Age: 30 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - At high risk for developing ovarian cancer, as determined by meeting criteria for 1 of the following: - Family history of at least 2 ovarian or breast* cancers among the patient and first- and second-degree relatives within the same lineage** - If breast cancer* is required to meet this criterion, at least 1 breast cancer* must be premenopausal (diagnosed at age 50 or under if menopausal status unknown) NOTE: **Multiple primary cancers in the same person satisfies this criterion - Ashkenazi Jewish ethnicity and meets criteria for 1 of the following: - Prior breast cancer* diagnosis - One first-degree or 2 second-degree relatives with breast* or ovarian cancer - If breast cancer is required to meet this criterion, at least 1 breast cancer* must be premenopausal (diagnosed at age 50 or under if menopausal status unknown) - Probability of BRCA1 or BRCA2 mutation greater than 20%, as determined by BRCAPRO 95% posterior probability interval - This criterion includes the following situations for which BRCAPRO is not required: - Tested positive for a BRCA1 or BRCA2 mutation (100% probability) - First- or second-degree relative with a BRCA1 or BRCA2 mutation NOTE: *Including ductal carcinoma in situ - No ovarian cancer, including low malignant potential cancers or primary papillary serous carcinoma of the peritoneum PATIENT CHARACTERISTICS: Age - 30 and over Performance status - Not specified Life expectancy - Not specified Hematopoietic - No hemophilia - No other bleeding disorders Hepatic - Not specified Renal - Not specified Pulmonary - No emphysema Other - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception - No psychiatric or psychological condition that would preclude giving informed consent - No concurrent untreated malignancy except nonmelanoma skin cancer - No other medical condition that would preclude blood draws (e.g., chronic infectious disease) PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - More than 3 months since prior adjuvant chemotherapy for cancer Endocrine therapy - Concurrent adjuvant hormonal therapy (e.g., tamoxifen, leuprolide, or goserelin) allowed Radiotherapy - More than 3 months since prior adjuvant radiotherapy for cancer Surgery - More than 3 months since prior intraperitoneal surgery (laparoscopy or laparotomy) - Prior prophylactic oophorectomy allowed Other - More than 5 years since prior treatment (excluding hormonal therapy) for metastatic malignancy - No concurrent participation in other ovarian cancer early detection trials
Total Enrollment:
Location and Contact Information:
Overall Study Official:
EdwardPartridge, Principal Investigator, UAB Comprehensive Cancer Center
University of Alabama at Birmingham Comprehensive Cancer Center *Recruiting*
Birmingham, Alabama, 35294-3300
United States
Recruiting Edward Partridge 205-934-0930
Additional Information:
Study ID Numbers: CDR0000353332; UAB-0120,UAB-120
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00080639
Other Ovarian Epithelial Cancer Studies:
1. Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
2. TLK286 Compared With Either Liposomal Doxorubicin or Topotecan as Third-Line Therapy in Treating Patients With Platinum-Refractory or Platinum-Resistant Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
3. Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
4. Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
5. Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Related Studies:
Other ovarian epithelial cancer Clinical Trials
Other Alabama Clinical Trials
Other Birmingham Clinical Trials
CA-125 in Screening Patients at High Risk for Ovarian Cancer
|
|
|
|
|
|
|
|
